ctDNA Minimal Residual Disease Testing | Diagnostics Market Intelligence

Description

List of Tables

Minimal residual disease testing is the most consequential idea to reach solid-tumor oncology in years: detect a recurrence months before imaging can, and treat the patient who actually needs treatment rather than the patient who statistically might. Japan has not merely watched this idea develop - it helped build the evidence. The GALAXY observational study and the CIRCULATE-Japan trial platform, run through Japanese surgical oncology networks, form one of the deepest national ctDNA datasets in the world, and in 2026 Japan became the first market to approve a tumor-informed MRD assay, Natera's Signatera, specifically to guide adjuvant decisions in colorectal cancer.

What remains unresolved is nearly everything that determines whether an approval becomes a practice. Reimbursement is undecided, and Japan's C1/C2/C3 test-pricing system has no natural shelf for a serial-monitoring assay of this kind. The randomized evidence on whether acting on a positive MRD result should change treatment is still maturing, which leaves guideline committees cautious. Competing assay architectures - tumor-informed personalized panels, tissue-free methylation tests, and hybrid approaches - make different trade-offs in sensitivity, logistics, and cost, and each has a corporate champion with a Japan strategy. Surgeons, who control the post-operative moment when MRD testing must begin, are not yet organized around a blood-draw workflow. And the questions that matter commercially - how often tests repeat, who pays for surveillance after curative surgery, whether expansion beyond colorectal cancer will follow - sit at the intersection of clinical evidence and Chuikyo politics.

This report maps the field end to end. It explains the biology and assay architectures in operational terms, reconstructs the GALAXY and CIRCULATE-Japan evidence base and the global randomized program around it, traces the PMDA approval pathway and the pending pricing decision, and models how testing would integrate into surgical, adjuvant, and surveillance workflows. Company chapters cover Natera, Guardant Health, Exact Sciences, and the domestic diagnostic players, with comparative context from the United States, Europe, and China.

The report serves diagnostics investors sizing the category, gastrointestinal oncology business-development teams planning MRD-era strategies, laboratory and hospital operators anticipating workflow change, and policy analysts tracking a pricing decision that will set precedent for an entire class.

Scope and Coverage: The report covers ctDNA minimal residual disease testing in Japan: assay technologies, clinical evidence, regulatory approval, reimbursement process, clinical integration, and competitive landscape. Colorectal cancer is the anchor indication; expansion pathways into other solid tumors are assessed.

Report Highlights:

Tumor-informed versus tissue-free assay architectures and their operational trade-offs
GALAXY and CIRCULATE-Japan evidence structure and the global randomized trial program
The 2026 Signatera PMDA approval pathway and intended-use scope
NHI pricing process status and precedent from earlier molecular tests
Clinical workflow integration from surgery through surveillance
Company profiles: Natera, Guardant Health, Exact Sciences, and Japanese diagnostics players

Product Code: JPH-043

Table of Content

1. Executive Summary

2. ctDNA Minimal Residual Disease Testing: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Natera (US) - Signatera personalized tumor-informed MRD assay; PMDA approval (2026) for CRC adjuvant monitoring. Guardant Health (US) - Reveal tissue-free MRD assay and Guardant360 liquid-biopsy portfolio. Exact Sciences (US) - Oncodetect MRD test with US payer coverage. Tempus (US) - xM and Northstar MRD assays in development and clinical use. Burning Rock (CN) - tumor-informed MRD and ctDNA evidence generation in China. Sysmex (JP) - OncoBEAM liquid-biopsy assays and Japan diagnostics infrastructure; potential MRD localization partner. NeoGenomics (US) - RaDaR ST tumor-informed MRD assay. Personalis (US) - NeXT Personal whole-genome-informed MRD assay. Roche/Foundation Medicine (CH) - ctDNA assay development and FoundationOne data integration. Genecast (CN) - MRD and liquid-biopsy assays in the China market. Daiichi Sankyo (JP) - sponsor interest in MRD-guided trial enrichment for ADC programs. National Cancer Center Japan (JP) - GALAXY and CIRCULATE-Japan academic sponsor generating the domestic evidence base.

Product Code: JPH-043

List of Tables

Table 1. Minimal residual disease concept and clinical use cases in solid tumors
Table 2. Adjuvant chemotherapy decision problem in stage II and III colorectal cancer
Table 3. Recurrence surveillance limitations of CT imaging and CEA monitoring
Table 4. ctDNA shedding biology and post-surgical detection windows
Table 5. Tumor-informed versus tissue-free assay architecture comparison
Table 6. Signatera assay design: whole-exome-guided personalized panel structure
Table 7. Guardant Reveal assay design: tissue-free methylation approach
Table 8. Exact Sciences Oncodetect assay design and validation program
Table 9. Tempus xM and other MRD assays under development
Table 10. Burning Rock and Chinese tumor-informed MRD programs
Table 11. Digital PCR versus NGS detection architectures for MRD
Table 12. Analytical validation frameworks: limits of detection and specificity requirements
Table 13. Sample logistics: tumor tissue requirements, plasma draws, and turnaround
Table 14. GALAXY study design, cohorts, and measurement schedule
Table 15. CIRCULATE-Japan platform structure and participating networks
Table 16. VEGA trial design: ctDNA-guided adjuvant de-escalation
Table 17. ALTAIR trial design: ctDNA-guided adjuvant escalation
Table 18. DYNAMIC trial design: randomized ctDNA-guided adjuvant therapy
Table 19. COBRA and CIRCULATE-US trial designs and status
Table 20. PEGASUS and other interventional MRD studies
Table 21. Observational evidence from Japanese colorectal cohorts outside GALAXY
Table 22. Evidence base in gastric, lung, and breast cancer MRD applications
Table 23. Evidence gaps: intervention benefit, lead time, and false positives
Table 24. PMDA review pathway for the Signatera application (2026)
Table 25. Intended-use statement and label structure of the approved assay
Table 26. Regulatory precedent: how earlier liquid biopsy tests were reviewed in Japan
Table 27. NHI price formation process for novel molecular tests
Table 28. C1/C2/C3 classification options for serial MRD testing
Table 29. Reimbursement precedent: Guardant360 CDx and OncoGuide panel pricing
Table 30. Serial testing cost accumulation and budget impact structure
Table 31. JSCCR and JSMO guideline positions on MRD-guided treatment
Table 32. Clinical decision points where MRD results would alter management
Table 33. Surgeon and oncologist workflow for post-surgical blood draws
Table 34. Ordering, logistics, and reporting workflow for personalized assays
Table 35. Centralized versus decentralized testing delivery models
Table 36. Multidisciplinary board integration of MRD results
Table 37. Patient consent and communication practices for MRD testing
Table 38. MRD use in clinical trial design as endpoint and stratification factor
Table 39. Pharma partnerships with MRD assay developers
Table 40. Natera Japan strategy and partnership structure
Table 41. Guardant Health Japan operations and MRD positioning
Table 42. Exact Sciences international MRD expansion plans
Table 43. Sysmex and domestic IVD company activity in MRD
Table 44. Reference laboratory capacity for MRD testing in Japan
Table 45. Health economics evaluation frameworks for MRD-guided adjuvant strategies
Table 46. Adoption scenarios for MRD testing under different reimbursement outcomes
Table 47. Expansion pathway from colorectal to other tumor types in Japan
Table 48. Regulatory and policy watchlist for MRD in Japan
Table 49. Research agenda: unresolved clinical and operational questions
Table 50. Cost-effectiveness study designs for MRD-guided adjuvant strategies

List of Figures

Figure 1. ctDNA release and clearance kinetics after curative surgery
Figure 2. MRD detection lead time relative to imaging recurrence
Figure 3. Adjuvant treatment decision tree with and without MRD information
Figure 4. Tumor-informed assay workflow from tissue to plasma surveillance
Figure 5. Tissue-free assay workflow and methylation signal architecture
Figure 6. Personalized panel design process for tumor-informed assays
Figure 7. Assay architecture comparison matrix across leading platforms
Figure 8. Sample logistics map from operating room to laboratory
Figure 9. GALAXY study schematic: cohorts and serial measurement points
Figure 10. CIRCULATE-Japan platform map linking interventional trials
Figure 11. VEGA trial schema and randomization structure
Figure 12. ALTAIR trial schema and treatment escalation logic
Figure 13. DYNAMIC trial randomization flow
Figure 14. Global interventional MRD trial landscape map
Figure 15. Evidence gap map for MRD-guided decision-making
Figure 16. PMDA review timeline for the first MRD approval
Figure 17. Intended-use population definition diagram
Figure 18. NHI price formation flow for novel molecular diagnostics
Figure 19. C1/C2/C3 classification decision tree applied to MRD
Figure 20. Reimbursement precedent timeline for molecular tests in Japan
Figure 21. Serial testing schedule and cumulative cost structure schematic
Figure 22. Guideline development pathway for MRD integration
Figure 23. Post-surgical testing decision points along the care pathway
Figure 24. Clinical workflow integration map for surgical departments
Figure 25. Ordering-to-reporting workflow for personalized MRD assays
Figure 26. Centralized versus hospital-laboratory delivery model comparison
Figure 27. Tumor board integration flow for MRD results
Figure 28. Patient communication pathway for MRD testing
Figure 29. MRD as a trial endpoint: regulatory logic schematic
Figure 30. Pharma-diagnostic partnership structures in MRD
Figure 31. Natera Japan go-to-market structure
Figure 32. Guardant Health Japan operational map
Figure 33. Competitive positioning framework for MRD platforms
Figure 34. Domestic diagnostics developer landscape in Japan
Figure 35. Reference laboratory network capacity map
Figure 36. Health economics model structure for MRD-guided adjuvant therapy
Figure 37. Adoption scenario tree under alternative pricing outcomes
Figure 38. Tumor-type expansion pathway map
Figure 39. Recurrence surveillance protocol redesign with MRD
Figure 40. False-positive and false-negative consequence framework
Figure 41. Test failure and insufficient-tissue pathway handling
Figure 42. MRD testing in the neoadjuvant and organ-preservation context
Figure 43. Stakeholder map: surgeons, oncologists, laboratories, payers
Figure 44. Policy timeline for molecular diagnostics reimbursement in Japan
Figure 45. International adoption comparison: US, Europe, Japan
Figure 46. China MRD development and regulatory environment
Figure 47. Research agenda map for MRD science and implementation
Figure 48. Report methodology and evidence hierarchy schematic
Figure 49. Expert-panel and guideline-committee review process for MRD evidence
Figure 50. Data flow from assay vendor to treating physician in MRD programs

ctDNA Minimal Residual Disease Testing | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. ctDNA Minimal Residual Disease Testing: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures